We Got a First Look at ‘Common Side Effects’ Season 2
If you missed Common Side Effects when it aired last year, it’s time to catch up with one of Adult Swim’s best and most offbeat shows in recent memory. And soon, it’s coming back for a second season, which Bennett, Hely, and cast members Martha Kelly (DEA Agent Harrington) and Joseph Lee Anderson (DEA Agent Copano) teased at the Common Side Effects panel this week at San Diego Comic-Con. “Early 2027” is the newly announced release window, and the show was far enough along to share a couple of early glimpses with the audience.
- ▪If you missed Common Side Effects when it aired last year, it’s time to catch up with one of Adult Swim’s best and most offbeat shows in recent memory.
- ▪And soon, it’s coming back for a second season, which Bennett, Hely, and cast members Martha Kelly (DEA Agent Harrington) and Joseph Lee Anderson (DEA Agent Copano) teased at the Common Side Effects panel this week at San Diego Comic-Con.
- ▪“Early 2027” is the newly announced release window, and the show was far enough along to share a couple of early glimpses with the audience.
Gizmodo files mainly under tech. We currently carry 474 of its stories.
Opening excerpt (first ~120 words) tap to expand
If you missed Common Side Effects when it aired last year, it’s time to catch up with one of Adult Swim’s best and most offbeat shows in recent memory. Co-creators Joe Bennett (whose art style will be familiar to fans of the late, great Scavengers Reign) and Steve Hely made a trippy thriller about a man who discovers a mushroom that can cure any ailment (including death), and the ensuing fallout as multiple parties fight over how to use and control that miraculous power. And soon, it’s coming back for a second season, which Bennett, Hely, and cast members Martha Kelly (DEA Agent Harrington) and Joseph Lee Anderson (DEA Agent Copano) teased at the Common Side Effects panel this week at San Diego Comic-Con.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Gizmodo.
Discussion
0 commentsMore from Gizmodo
